| Literature DB >> 28133477 |
Duc Trong Quach1, Mai Ngoc Luu1, Toru Hiyama2, Thuy-HuongThi To3, Quy Nhuan Bui3, Tuan Anh Tran3, Binh Duy Tran3, Minh-Cong Hong Vo4, Shinji Tanaka5, Naomi Uemura6.
Abstract
Aims. To investigate H. pylori infection rate and evaluate a combined set of tests for H. pylori diagnosis in Vietnamese patients with acute peptic ulcer bleeding (PUD). Methods. Consecutive patients with acute PUB were enrolled prospectively. Rapid urease test (RUT) with 3 biopsies was carried out randomly. Patients without RUT or with negative RUT received urea breath test (UBT) and serological and urinary H. pylori antibody tests. H. pylori was considered positive if RUT or any noninvasive test was positive. Patients were divided into group A (RUT plus noninvasive tests) and group B (only noninvasive tests). Results. The overall H. pylori infection rate was 94.2% (161/171). Groups A and B had no differences in demographic characteristics, bleeding severity, endoscopic findings, and proton pump inhibitor use. H. pylori-positive rate in group A was significantly higher than that in group B (98.2% versus 86.7%, p = 0.004). The positive rate of RUT was similar at each biopsy site but significantly increased if RUT results from 2 or 3 sites were combined (p < 0.05). Conclusions. H. pylori infection rate in Vietnamese patients with acute PUB is high. RUT is an excellent test if at least 2 biopsies are taken.Entities:
Year: 2017 PMID: 28133477 PMCID: PMC5241452 DOI: 10.1155/2017/3845067
Source DB: PubMed Journal: Gastroenterol Res Pract ISSN: 1687-6121 Impact factor: 2.260
Demographics and clinical characteristics (n = 171).
| Demographics and clinical characteristics |
|
|---|---|
| Age (mean ± SD) | 55.4 ± 17.3 |
| Male | 131 (76.6) |
| Medical use before admission | |
| NSAIDs | 43 (25.1) |
| PPIs ≤ 2 weeks | 28 (16.4) |
| Antibiotics ≤ 4 weeks | 13 (7.6) |
| Prior history of peptic ulcers | 42 (24.6) |
| Prior history of | 12 (7.0) |
| Presenting symptoms | |
| Hematemesis | 88 (51.5) |
| Melena | 77 (45) |
| Hematochezia | 6 (3.5) |
| Preendoscopic PPIs use | |
| High-dose, intravenous | 133 (77.8) |
| Low-dose, intravenous | 8 (4.6) |
| Oral | 3 (1.8) |
| None | 27 (15.8) |
| Hemodynamic instability at admission (heart rate > 100 beats per minute and/or systemic blood pressure < 100 mmHg) | 47 (27.5) |
| Transfusion requirement | 47 (27.5) |
Endoscopic setting and findings (n = 171).
| Endoscopic setting and findings |
|
|---|---|
| Timing | |
| <12 h | 138 (80.7) |
| 12–24 h | 16 (9.4) |
| >24 h | 17 (9.9) |
| Presence of blood in gastrointestinal tract | 75 (43.9) |
| Location of ulcer | |
| Gastric | 73 (42.7) |
| Duodenal | 84 (49.1) |
| Gastric and duodenal | 14 (8.2) |
| Endoscopic stigmata | |
| Spurting | 1 (0.6) |
| Oozing | 19 (11.1) |
| Visible vessel | 25 (14.6) |
| Adherent clot | 56 (32.7) |
| Red spot | 17 (9.9) |
| Clean-based | 53 (31.0) |
Figure 1H. pylori testing in Vietnamese patients with acute peptic ulcer bleeding.
The characteristics of patients in groups A and B.
| Characteristics | Group A | Group B |
|
|---|---|---|---|
| Age (mean ± SD) | 54.7 ± 17.6 | 56.1 ± 16.8 | 0.696 |
| Male | 84 (75.7) | 47 (78.3) | 0.695 |
| Prior history of gastroduodenal ulcers | 28 (25.2) | 14 (23.3) | 0.784 |
| Prior history of | 8 (7.2) | 4 (6.7) | 1.000 |
| Medical use before admission | |||
| NSAIDs | 28 (25.2) | 15 (25.0) | 0.974 |
| PPIs within 2 weeks | 21 (18.9) | 7 (11.7) | 0.221 |
| Antibiotics within 4 weeks | 10 (9.0) | 3 (5.0) | 0.547 |
| Hemodynamic instability at admission (heart rate > 100 beats per minute or systemic blood pressure < 100 mmHg) | 29 (26.1) | 18 (30.0) | 0.219 |
| Preendoscopic PPIs use | |||
| High-dose, intravenous | 89 (80.2) | 44 (73.3) | 0.136 |
| Low-dose, intravenous | 6 (5.4) | 2 (3.3) | |
| Oral | 3 (2.7) | 0 (0) | |
| None | 13 (11.7) | 14 (23.3) | |
| Timing of endoscopy | |||
| <12 h | 84 (75.7) | 54 (90.0) | |
| 12–24 h | 13 (11.7) | 3 (5.0) | 0.077 |
| >24 h | 14 (12.6) | 3 (5.0) | |
| Presence of blood in endoscopy | 52 (46.8) | 23 (38.3) | 0.284 |
| Location of ulcer | |||
| Gastric | 49 (44.1) | 24 (40.0) | 0.763 |
| Duodenal | 54 (48.6) | 30 (50.0) | |
| Gastric and duodenal | 8 (7.2) | 6 (10.0) | |
| Endoscopic stigmata | |||
| Spurting | 1 (0.9) | 0 (0) | 0.448 |
| Oozing | 13 (11.7) | 6 (10.0) | |
| Visible vessel | 20 (18.0) | 5 (8.3) | |
| Adherent clot | 33 (29.7) | 23 (38.3) | |
| Red spot | 12 (10.8) | 5 (8.3) | |
| Clean-based | 32 (28.8) | 21 (35.0) | |
|
| 109 (98.2) | 52 (86.7) | 0.004 |
RUT results with specimens taken from different biopsy sites.
| Biopsy sites |
|
|---|---|
| Single biopsy site | |
| 1 (midantrum, greater curvature) | 93 (83.8) |
| 2 (low-corpus, greater curvature) | 100 (90.1) |
| 3 (midcorpus, greater curvature) | 95 (85.6) |
| Two biopsy sites (combined results) | |
| 1 & 2 | 108 (97.3) |
| 1 & 3 | 105 (94.6) |
| 2 & 3 | 106 (95.5) |
| Three biopsy sites (combined result) | |
| 1, 2, and 3 | 109 (98.2) |
Figure 2RUT results from single specimen versus combined specimens from two biopsy sites.